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Background Treatments for migraine headaches in cardiac patients are limited. Calcitonin gene-related peptide (CGRP) is a potent vasodilator. 
Telcagepant (MK-0974) is a novel CGRP receptor antagonist being evaluated for treatment of acute migraine headache. It is unknown whether 
a CGRP receptor antagonist reduces compensatory vasodilatory capacity during myocardial ischemia. The aim of this study was to determine if 
telcagepant adversely affects exercise parameters of myocardial ischemia.
Method The study was a double-blind, placebo-controlled, 2-period, single-dose crossover in 61 patients with reproducible exercise induced angina 
and treadmill exercise time. In each period, patients received a single oral dose of telcagepant (N=14, 900 mg or N=46, 600 mg) or placebo. 
Patients were randomized to treatment and in each period performed a Bruce treadmill exercise test at Tmax post telcagepant. The primary endpoint 
was designed to test the lower bound of the 2-sided 90% confidence interval (equivalent to a 1-sided lower 95% confidence interval) for a total 
exercise duration treatment difference (MK0974 - Placebo) > -60 seconds.
Results Data were analyzed for all subjects and stratified by dose. Mean total exercise duration for telcagepant was 405.38 seconds (95% CI: 
375.91, 434.85) and for placebo was 412.28 seconds (382.72, 441.85); mean treatment difference (telcagepant - placebo) was -6.90 seconds 
(90% CI: -17.66, 3.86). The mean treatment difference in total exercise duration (600 mg telcagepant - placebo) was -10.61 seconds (90% CI: 
-22.94, 1.72). The mean treatment difference in total exercise duration (900 mg telcagepant - placebo) was 4.75 seconds (90% CI: -16.69, 26.20). 
There were no significant between-treatment differences in exercise time, maximum exercise heart rate, maximum ST segment depression (STD) or 
time to 1 mm STD among pooled data or upon stratification for dose.
Conclusion The findings suggest that antagonism of the CGRP receptor has no statistically significant effect on compensatory vasodilatory capacity 
during myocardial ischemia as assessed by exercise duration, chest pain or STD in patients with chronic angina and limiting exercise-induced 
cardiac ischemia.
